+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CoMentis Inc - logo

CoMentis specializes in the development of small-molecule drugs to treat neurovascular diseases with a focus on Alzheimer's disease and schizophrenia. They cover the research and development spectrum from initial drug design through manufacturing and clinical trials. The company, with headquarters in South San Francisco, was formed by the merger of Zapaq, Inc. and Athenagen, Inc. in 2006. It is also working on nicotinic acetylcholine receptor modulators for the treatment of cognitive disorders.

Beta Secretase Inhibitor -Pipeline Insight, 2019 - Product Thumbnail Image

Beta Secretase Inhibitor -Pipeline Insight, 2019

  • Drug Pipelines
  • January 2019
  • 60 Pages
From
From
From
Obesity - Pipeline Review, H2 2019 - Product Thumbnail Image

Obesity - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 567 Pages
From
Smoking Addiction - Pipeline Review, H2 2017 - Product Thumbnail Image

Smoking Addiction - Pipeline Review, H2 2017

  • Drug Pipelines
  • December 2017
  • 89 Pages
From
Smoking Addiction - Pipeline Review, H1 2017 - Product Thumbnail Image

Smoking Addiction - Pipeline Review, H1 2017

  • Drug Pipelines
  • June 2017
  • 86 Pages
From
Wet AMD- Pipeline Insight, 2018 - Product Thumbnail Image

Wet AMD- Pipeline Insight, 2018

  • Drug Pipelines
  • May 2018
  • 106 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • May 2018
  • 217 Pages
From
Endotoxemia Global Clinical Trials Review, H1, 2019 - Product Thumbnail Image

Endotoxemia Global Clinical Trials Review, H1, 2019

  • Clinical Trials
  • May 2019
  • 66 Pages
From
  • 10 Results (Page 1 of 1)
Loading Indicator
adroll